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Abstract
Purpose of Review To describe models of integrated and co-located care for opioid use disorder (OUD), hepatitis C (HCV), and
HIV.
Recent Findings The design and scale-up of multidisciplinary care models that engage, retain, and treat individuals with HIV,
HCV, and OUD are critical to preventing continued spread of HIVand HCV. We identified 17 models within primary care (N =
3), HIV specialty care (N = 5), opioid treatment programs (N = 6), transitional clinics (N = 2), and community-based harm
reduction programs (N = 1), as well as two emerging models.
Summary Key components of such models are the provision of (1) medication-assisted treatment for OUD, (2) HIV and HCV
treatment, (3) HIV pre-exposure prophylaxis, and (4) behavioral health services. Research is needed to understand differences in
effectiveness between co-located and fully integrated care, combat the deleterious racial and ethnic legacies of the “War on
Drugs,” and inform the delivery of psychiatric care. Increased access to harm reduction services is crucial.
Keywords Opioid use disorder . Hepatitis C virus . HIV . Integrated care . Co-located care
Introduction
The opioid epidemic in the USA, especially the rise in injection
drug use (IDU), has ushered in a volatile and evolving risk
environment for HIVand hepatitis C (HCV) [1–5], particularly
in rural areas [2, 6]. In 2016, over 2 million Americans had an
opioid use disorder (OUD), with 11.5 million people aged
12 years or older misusing prescription painkillers and
948,000 using heroin and/or synthetic opioids such as fentanyl
[7]. Currently, 10–20% of people who misuse prescription opi-
oids escalate to injection [8, 9], contributing to substantial risk
for new HIVand HCVoutbreaks due to the sharing of contam-
inated injection equipment and sexual risk behaviors [10].
This HIV/HCV risk environment is epitomized by the out-
break in Scott County, Indiana beginning in late 2014 [11].
HIV incidence, attributed to shared injection equipment, rose
from 5 to 181 cases in 2015. Over 90% were co-infected with
HCV. Nationally, 2392 new HIV cases in people who inject
drugs (PWID) were reported in 2015 [3]. HCV incidence tri-
pled between 2010 and 2015, primarily due to opioid-related
drug injection [12]. HIVand HCV prevention efforts for indi-
viduals with OUD have been challenged by lack of health
insurance [13], limited access tomedication-assisted treatment
(MAT) [14, 15], fragmented care [16], psychiatric co-
morbidities [3], and the syndemic nature of these overlapping
epidemics where services that are most needed do not exist
[16, 17].
The design and scale-up of integrated or co-located, multi-
disciplinary care models that engage and retain individuals is
critical to the success of HIV and HCV prevention strategies
[16, 18, 19]. Key components of suchmodels are (1) provision
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of MAT to reduce risks for acquiring HIV and HCV and to
prevent HCV re-infection, (2) HIV and HCV treatment to
prevent transmission within injection drug and sexual net-
works (“treatment as prevention, TasP”), (3) access to HIV
pre-exposure prophylaxis (PrEP), (4) behavioral health ser-
vices that address psychiatric co-morbidities and increase en-
gagement with and adherence to care, and (5) access to harm
reduction services (i.e., sterile injection equipment and nalox-
one) [16, 18–22]. This “twenty-first century” opioid epidemic,
initially demographically and geographically different from
the “twentieth century” one, is characterized by PWID net-
works among rural, primarily white populations [2, 23, 24],
although it has recently extended to urban minority commu-
nities [25••]. This means that the delivery of integrated or co-
located care will need to be tailored to different populations,
geographical locations, and the surrounding, typically re-
source-poor, healthcare environments [26••].
Understanding models of care that have integrated or co-
located HIV, HCV, and OUD services is crucial for optimizing
initiatives to expand access to care. This paper presents current
models of care within five treatment settings: primary care,
HIV care, specialized opioid treatment programs (OTPs), tran-
sitional clinics, and community-based harm reduction pro-
grams. Program characteristics, as well as a representative
model of care for each treatment setting, are described to guide
future program development, followed by a discussion of
emerging approaches and areas that need further research.
Methods
Search Strategy We searched the literature describing care
models that included MAT (methadone, buprenorphine, nal-
trexone), HIV, and/or HCV services from August 2007 to
September 2017 using Ovid Medline, Scopus, PsychInfo,
and EMBASE databases for articles and conference abstracts
(see Appendix Table S.1 for search terms). We also reviewed
reference lists of key papers describing integrated/co-located
models of care. To be included, studies had to describe a
health service(s) delivery program that (1) was located in the
USA, (2) provided MAT, (3) provided HIVand/or HCV care,
(4) was designed for adults (≥ 18 years), and (5) was written in
English or Spanish.
Data Extraction Selected studies were classified as describing
care provided in one of the five treatment settings listed above.
For each model, data were extracted to describe the popula-
tion(s) served, the OUD treatment agents available, and the
extent or co-location of mental healthcare integration and
HIV/HCV care.
Selection of Representative Model For each treatment setting,
we selected a representative model of care based on their
similarity to other programs within the given category, their
innovativeness, or their focus on HIV and/or HCV care.
Results
We identified 1394 abstracts and reviewed 141 full text
articles and conference abstracts, of which 41 described
17 unique, co-located or integrated models of care (5 HIV
specialty care, 3 primary care, 6 OTP, 2 transitional
clinics, and 1 community-based harm reduction program),
and two emerging models. Details of each of model of
care are provided in the Appendix (Table S.2). General
characteristics of the populations served by treatment set-
ting are provided in Table 1. Pharmacological agents used
to treat OUD are described in Table 2.
Primary Care
A key strategy to expand access to comprehensive care for
individuals with OUD, and thereby decrease the risk of HIV
and HCV transmission, is the integration or co-location of
treatment for all three conditions into primary care settings
[26••], particularly in rural areas that lack specialty opioid
and infectious diseases treatment centers. Key advantages of
the delivery of OUD, HIV, and HCV treatment in the primary
care setting are that this model lowers the threshold for patient
entry and enhances continuity of care [27, 28]. As many indi-
viduals with opioid misuse or addiction seek treatment for
physical ailments, primary care providers (PCPs) play a cru-
cial role in identifying substance use disorders (SUDs) and
expanding treatment accessibility [29, 30]. Physicians who
complete 8 h of training and nurse practitioners and physician
assistants who complete 24 h of training may obtain a Drug
Enforcement Administration (DEA) waiver to prescribe
buprenorphine or buprenorphine/naloxone, the mainstay of
MAT [31, 32]. In addition to treating OUD, buprenorphine/
naloxone also has been shown to reduce HCV reinfection
[33]. For individuals with OUD who do not want
buprenorphine, any clinician can prescribe extended-release
naltrexone (XR-NTX), an evidence-based opioid antagonist
treatment for OUD that requires successful completion of su-
pervised withdrawal (“detox”) before starting treatment.
Representative Example:
LocationA federally qualified health center (FQHC) affiliated
with Montefiore Medical Center in the Bronx, New York, that
serves over 9000 adults annually [34•].
MAT Services A team of internists and clinical pharmacists con-
duct screening and onsite buprenorphine/naloxone treatment, in-
cluding induction, stabilization, and maintenance. Clinical
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pharmacists, internists, or both together conduct follow-up visits.
Motivational interviewing is incorporated into medical visits to
promote adherence and engagement in care. Clinical judgment
drives urine drug testing (UDT), but no one is discharged from
treatment solely due to UDT results [34•, 35•].
Psychiatric Services Co-located.
HIV Services Testing and treatment are provided, supported by
Ryan White Care Act funding [34•, 35•].
HCV Services HCVevaluation and treatment are provided by a
physician trained in both HCV care and addiction medicine,
supported by a care coordinator. Referrals come from PCPs
and nearby syringe exchange programs. Treated patients are
enrolled in the NYC Department of Health’s Check Hep C
Patient Care Coordinator Program which provides a full time
care coordinator to facilitate linkage and retention in HCV
care, psychosocial assessment, health education, navigation
of insurance prior authorization and claims, and applications
to patient assistance programs for medication [34•].
HIV Specialty Care Clinics
HCV prevalence among people living with HIV/AIDS
(PLWH) is about 25% nationally [36], and HIV/HCV co-
infection among PWID ranges between 50 and 90% [37]; both
vary by location and population served. Specialty HIV care
sites, which typically provide access to infectious disease ex-
perts, are an ideal setting to provide integrated or co-located
HIV, HCV, and OUD treatments in communities with a high
prevalence of HIVamong PWID.
Acknowledging the importance of integrating substance
use treatment at HIV care sites, the HIV/AIDS Bureau of
the Health Resources and Services Administration
(HRSA) funded the Buprenorphine and HIV Care
Evaluation and Support (BHIVES) initiative from 2004
to 2009. BHIVES developed and implemented integrated
HIV care and buprenorphine/naloxone treatment at ten
sites [38]. Qualitative interviews with patients at one site
suggest that they felt positively about the provision of
MAT at an HIV care site, as it allowed access to OUD
treatment in a setting that did not care exclusively for
individuals with SUDs. In a longitudinal analysis, HIV
patients prescribed and maintained on buprenorphine/
naloxone were significantly more likely to be prescribed
antiretroviral therapy (ART) and to achieve viral suppres-
sion than those not retained on MAT [39]. Key features
associated with success at each clinic involved ongoing
education and support to providers [40] and a “glue”
person who coordinated care for these more complex
patients [38].
Table 2 Characteristics of pharmacologic agents for OUD treatment
Agent Mechanism Dosing schedule Location availability Regulations
Methadone μ receptor full agonist Daily OTP Methadone must be provided at
a federally regulated specialty OTP
Buprenorphine
(buccal or sublingual)





programs, HIV care sites
Physicians must complete 8-h training
and receive a DEAwaiver
Nurse practitioners and physician
assistants must complete 24 h of
training and received a DEAwaiver
Buprenorphine
(implantable)




Physicians must have waiver
(8-h training required)
Naltrexone (oral) μ receptor antagonist Daily Office-based, OTP, HIV
care sites
Any provider who can prescribe
medications
Naltrexone (injection) μ receptor antagonist Once per month Office-based, OTP, HIV
care sites
Any provider who can prescribe
medications
Table 1 Characteristic of care models by treatment setting
Treatment setting Populations served Available MAT
Office-based
primary care




HIV care sites 1. Urban populations and/or
populations with a high
prevalence of HIV
2. HIV-positive individuals who







2. Individuals with anOUDwho







1. Communities with a high
prevalence of PWID
2. PWID and individuals
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Representative Example
Location A hospital-based HIV clinic in Providence, Rhode
Island. The clinic cares for 1400 HIV-infected patients, of
whom approximately 30% have OUD [41•].
MAT Services Patients are regularly informed of onsite
buprenorphine/naloxone treatment through nurse-led educa-
tional sessions and during regularly scheduled HIV care ap-
pointments. The clinic also coordinates with nearby substance
use treatment facilities.
Psychiatric Services Psychologists and social workers provide
both individual care and support groups [42].
HIV Services Specialty HIV care is provided by HIV physi-
cians. The clinic, embeddedwithin a hospital facility, provides
HIV testing, counseling, treatment, education, and case man-
agement [42].
HCV Services All patients are screened, evaluated, and provid-
ed treatment onsite through the HIV program’s co-located
Coinfection Clinic [41•].
Specialty OTPs
Opioid treatment programs (OTPs) are federally quali-
fied programs that specialize in methadone maintenance
therapy (MMT) [43]. OTPs can be funded either direct-
ly or indirectly through public sources or through fee-
for-service models. An advantage of MMT in the public
setting is that it is usually provided with minimal direct
expense to the patient [44]. MMT requires daily visits
to receive methadone; although with time and duration
of abstinence, patients can take home doses for self-
administration [45]. OTPs may also be staffed by other
healthcare providers who can provide primary or spe-
cialty care for a range of co-morbid psychiatric condi-
tions, HIV and HCV [46•]. HCV-infected individuals
who are treated while receiving MAT have achieved
high rates of sustained virologic response (SVR, or
cure) irrespect ive of continued drug use [33],
underscoring the fact that sobriety should not be a pre-
condition of HCV treatment.
Representative Example
Location The APT Foundation, a non-profit addiction treat-
ment program in Connecticut, where the majority of patients
have an OUD [46•]. Injection equipment disposal boxes are
installed in exam rooms.
MAT Services All patients undergo an initial medical and psy-
chiatric evaluation. The program provides methadone or
buprenorphine to over 5000 patients [46•].
Psychiatric Services Psychiatric care, including psychotherapy,
individualized treatment counseling and medication, is avail-
able [46•].
HIV Services HIV testing, counseling, and treatment are pro-
vided; referrals can also be made to specialty clinics.
HCV Services HCV testing, counseling, and treatment are pro-
vided. Free voluntary HCV screening is provided, and for
those with infection, their contacts may be approached anon-
ymously. There is supportive care from social workers and
psychiatrists as needed [46•].
Community-Based Harm Reduction Programs
Syringe service programs (SSPs, also known as syringe
or needle exchange programs) are a critical component of
HIV, HCV, and overdose prevention [47–52]. SSPs pro-
vide non-judgmental, free, accessible testing and care
services to PWID who often do not have contact with
medical services or who shun medical care because of
stigma and prior poor treatment [53]. A recent study
found that 50% SSP coverage within the USA would
be cost-effective and avert up to 35,000 HIV infections
over 20 years [54]. For maximal impact, SSPs must pro-
vide a robust array of health services [55–57], including
HIV testing linked to both primary (e.g., sterile equip-
ment, addiction treatment, PrEP) and secondary HIV pre-
vention (e.g., TasP), and HCV testing with linkage to
parallel services. A modeling study found that a signifi-
cant reduction in HIV transmission within a community
with an established epidemic requires that SSPs provide
multiple services, including linkage to healthcare and
MAT [55]. In parallel, a meta-analysis concluded that
SSPs that provide only sterile syringes are insufficient
to prevent the spread of HCV; rather, SSPs must also
provide sterile injection equipment (i.e., cottons,
cookers), as well as other harm reduction services (i.e.,
safe sex, condoms, and sterile injection education) [56].
A network model found that if HCV prevalence within a
PWID community is ≤ 60%, then treating ≥ 12% of
HCV-positive PWID in the network would eliminate
HCV within 10 years [58]. Together, these data support
the concept that the ideal SSP is a “one-stop shop” that
provides harm reduction, HIV and HCV testing and link-
age to services and linkage to OUD treatment services.
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Representative Example
Location A mobile medical clinic and an associated fixed site
clinic in Connecticut. Bilingual (English/Spanish) case man-
agers provide outreach services using a minivan [59•].
Harm Reduction Services Sterile injection equipment, con-
doms, and rapid HIV and HCV testing are provided at both
sites. Naloxone, overdose prevention education, and safe sex
education are offered at each visit.
MAT Services Maintenance with buprenorphine/naloxone or
naltrexone (XR-NTX) is provided at both sites.
Psychiatric Services Social workers and psychiatric nurse prac-
titioners provide mental health counseling at the fixed site
clinic.
HIV Services HIV treatment and case management is provided
at both sites, and ART is dispensed as directly administered
therapy [59•]. There are no specialty services for complicated
HIV patients; however, linkage to off-site specialty HIV care
is available.
HCV Services Rapid HCV tests are provided. Outreach
workers provide case management services and linkage to
HCV treatment.
Transitional Clinics
Individuals transitioning from criminal justice settings (CJS)
back to the community have a disproportionately high preva-
lence of HIV, HCV, substance use, and psychiatric illness (for
review, see [60]). One in six PLWH transitions through a
prison or jail annually [61]. While most PLWH achieve viral
suppression within the CJS [62], linkage to and retention in
care post-release are suboptimal [63], with relapse to drug and
alcohol use associated with poor ARTadherence and retention
in care [64]. Moreover, release from prison is associated with
extraordinary mortality primarily due to overdose fatality, es-
pecially within the first 2 weeks post-release.
Like HIV, people with HCVare concentrated in CJS; 11 to
37% have HCV, representing 30% of the estimated 5.7 to 6.5
million cases in the USA [65]. HCV treatment within prison
has been feasible with good outcomes [66], and newer data
using direct-acting antivirals (DAAs) in New York confirm
earlier findings [67]. Nonetheless, in 2015, less than 1% of
prisoners known to be HCV-positive were provided treatment
while incarcerated, largely due to the high cost of DAA and
limited funding for treatment [68]. Accordingly, many in-
mates with untreated HCV transition into the community,
challenging linkage to care efforts and potentially fueling on-
ward HCV transmission, undermining both the health of the
individual and the community.
This evidence underscores the importance of transitional
clinics specifically designed to care for individuals who have
recently been released from incarceration, with the aim of
optimizing care coordination between the CJS and the com-
munity. Transitional clinics can increase engagement and re-
tention in care and will have the greatest impact in communi-
ties with high rates of incarceration. Importantly, this model
may help address current racial disparities in access to HIV,
HCV, and OUD care, as well as treatment outcomes among
black individuals, who have the highest rate of new HIV in-
fections and AIDS diagnoses [69].
Representative Example
Location The Bronx Transitions Clinic (BTC) operates an
“open access” clinic from an federally qualified health center
(FQHC) affiliated with Montefiore Medical Center. The pro-
gram is a collaboration between the clinic and the Osborne
Association, a community-based organization that screens in-
mates for chronic health conditions and initiates case manage-
ment while they are still incarcerated. The BTC provides a
range of services on a sliding fee scale. Specific educational
programs help facilitate community reentry. Formerly incar-
cerated community health workers are employed to provide
health education, social support, and care coordination [70•,
71•].
MAT Services All individuals with OUD are offered
buprenorphine/naloxone.
Psychiatric Services Provided onsite.
HIV ServicesARTand casemanagement are provided; approx-
imately 20% are HIV-positive. The Osborne Association pro-
vides case management through outreach workers.
HCV Services Treatment is provided onsite.
Emerging Models
The volatile nature of the opioid epidemic, its associated risk
of new HIV and HCV outbreaks, the availability of new, ef-
fective treatments, and the rural location of many PWID ne-
cessitate the development of innovative care models.
Expanded access to care in rural areas is desperately needed.
In 2012, it was estimated that state-level rates of
buprenorphine treatment capacity ranged from 0.7 to 13.8
patients per 1000 individuals aged 12 years or older [72].
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All but two states had a rate of past year OUD greater than
their treatment capacity rate, resulting in an enormous gap
between treatment need and capacity of 1.4 million people
[72]. A survey of 108 PCPs in 2014 found that while 80%
reported that they knew of opioid-dependent patients and 73%
admitted to feeling a personal responsibility as a primary care
doctor to treat addiction, only 10% prescribed MAT [73]. The
most commonly cited reasons for not providing MATwas the
belief that treating addiction is difficult, a lack of confidence in
prescribing according to guidelines, and a low level of staff
preparedness. Similar barriers exist for the provision of HIV
andHCV care, particularly for individuals with OUD [74–76].
A second factor contributing to the treatment gap is the
changing demographic characteristics and geographic distri-
bution of individuals with OUD [23, 77•]. Historically, opioid
use was largely concentrated in urban areas among minority
populations, whereas currently it is concentrated among pri-
marily white populations in suburban and rural areas [23]. In
an analysis of county-level vulnerability to HIV and HCV
infections, 220 rural counties were defined as vulnerable
[77•], reflecting the changing geographic distribution of both
opioid misuse and addiction, and the associated increase of
IDU.
There are two emerging models of care that hold promise
for expanding access to integrated care services by utilizing
internet and cell phone technologies: Project ECHO (a tele-
education program) [78] and a A-CHESS (an mHealth phone
application) [79•].
Telemedicine and Tele-education
Standard telemedicine via two-way videoconferencing per-
mits direct interaction between patients and specialists in dif-
ferent locations. It is an adaption of the traditional brick-and-
mortar “hub and spoke model”, in which a specialty care cen-
ter provides support and resources to several lower-tier care
centers throughout a geographic area.
Project Extension for Community Care Outcomes (Project
ECHO), a tele-education model developed at the University of
New Mexico, utilizes videoconference technology to help
PCPs gain the knowledge and self-efficacy to deliver complex
specialty medical care. A group of interdisciplinary specialists
located at a distant “hub” video links with community PCPs
for regularly scheduled didactic sessions and case presenta-
tions. ECHO creates “knowledge networks” that promote
learning and the rapid dissemination of current treatment re-
search and epidemiological trends [80]. It has been proven
effective for HCV treatment and has been applied to a range
of other conditions [80–82]. An Integrated Addictions and
Psychiatry Tele-ECHO clinic has recruited physicians to com-
plete the 8-h buprenorphine training, thus allowing them to
provide MAT. Since 2006, over 175 physicians in New
Mexico have completed training through this program [80].
Tele-education may be particularly useful in rural or other
underserved areas where access to specialty care or academic
medical centers is limited.
mHealth Phone Apps
mHealth—the use of mobile apps and text messaging to pro-
mote health—has grown dramatically in the past decade.
While mHealth approaches lack rigorous evaluation and are
still early in development, mHealth holds the promise of pro-
viding cost-effective tools to manage care and promote health
behaviors [83–85]. mHealth can provide a private communi-
cation platform that permits flexible reminders and content
[86–88]. mHealth acceptability has been investigated among
people who use drugs (PWUD) and are engaged in HIV or
SUD treatment [88]. Results suggest that the majority of
PWUD are interested in mHealth to promote health and ad-
herence to HIV treatment. In the context of HIV, HCV, and
OUD care, mHealth apps provide a platform to virtually inte-
grate care by facilitating communication and the dissemina-
tion of information between patients and providers with po-
tential to increase care coordination, both between care teams
from different clinics and among team members at a clinic
with co-located services. This approach, however, is limited
by cost (usage of minutes) and lack of cell phone coverage in
some rural areas.
A-CHESS is a smartphone app designed by researchers at
the University of Wisconsin-Madison and is being evaluated
for reducing illicit opioid use among individuals receiving
MAT [79]. The app provides a platform for information shar-
ing and SUD treatment support tools, such as cognitive be-
havioral therapy booster sessions; GPS-based location moni-
toring to predict locations that may place the individual at risk
of drug use or unsafe sex; a “help” button that shows a list of
preapproved supports including phone numbers; and distrac-
tive activities. For participants who are HIVand/or HCV pos-
itive, A-CHESS delivers health education content, and links to
clinical care/case-management services. While still in devel-
opment, it is a promising mHealth strategy to coordinate a
patchwork of treatment services and support, especially in
rural areas.
Research Gaps and Future Directions
Our review identified several areas with limited information.
The development of strategies to increase communication and
teamwork across care teams may increase retention and suc-
cess in care and may be more rewarding to both patients and
practitioners. This is particularly important for the expansion
of care in rural communities. Research is needed on optimal
approaches to delivering harm reduction services in isolated
rural communities, as well as strategies to effectively fold
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addiction, HIV, and HCV care into rural primary care practices
that may already be overburdened and under-resourced.While
tele-education has proven to be an exciting and effective strat-
egy, additional research is needed to identify best practices
and limitations, especially in areas without reliable internet
access. Figure 1 depicts the potential pathway of integration
from separate specialty clinics to a model of integrated care,
supported by tele-education platforms.
Secondly, no studies have evaluated differing levels of en-
gagement across racial, ethnic, and gender groups. Data are
needed to better engage and care for diverse populations to
prevent HIVand HCVamong individuals with OUD. Work is
especially needed to address the deleterious racial and ethnic
legacies of the “War on Drugs”, as well as the pervasive stig-
ma and distrust surrounding treatment—both for addiction
and mental health care.
Third, research is needed to inform the delivery and inte-
gration or co-location of psychiatric care for a population with
OUD and other co-morbidities. Information on how to best
treat anxiety and depression among individuals with OUD and
HIV is needed to inform treatment paradigms that do not ex-
acerbate substance use, such as combined opioid and benzo-
diazepine dependence. Another significant barrier to the scale-
up of integrated models of care is cost. To address this, future
studies should consider including a budget impact analysis as
part of the evaluation process. At a system-level approach,
health insurance and payment reform are needed to allow
reimbursement for care by mid-level practitioners, outreach
workers, and peer navigators within integrated or co-located
models of care, as well as telemedicine services.
Finally, increasing access to harm reduction services is es-
sential to preventing HIVand HCV, including access to sterile
injection equipment and a range of treatment options for OUD
and HIV/HCV. Expansion of funding and political support is
needed for developing innovative harm reduction programs,
including pharmacy-based syringe exchange and increased
provision of syringe prescriptions by clinicians.
Limitations
Our review has several limitations. Due to the nature of a
literature search, our description of care models is biased to-
ward interventions connected with academic research institu-
tions. While we included conference abstracts and searched
the “gray literature” (materials and research produced by or-
ganization outside of traditional peer-reviewed academic pub-
lishing) for descriptions of care models not fully described in
peer-reviewed articles, our search may not have captured all
integrated or co-located treatment paradigms. Secondly, we
restricted our search to models of care within the USA to
provide examples of models most relevant to the current opi-
oid epidemic. International programs, however, provide other
examples of effective care models. Future research should
look to incorporating aspects of successful international
models to inform program development in the USA. Lastly,
none of the models explicitly addressed provision of PrEP.
Conclusion
The design and scale-up of integrated or co-located, multidis-
ciplinary care models that engage and retain individuals in
HIV, HCV, OUD, and mental health care are critical to
preventing the continued spread of HIVand HCV in the con-
text of the current opioid epidemic. Key components of such
Fig. 1 Steps toward HIV, opioid
use disorder (OUD), and hepatitis
C virus (HCV) care integration.
aCo-located services include
models that provide two or more
services at the same site. bPartial
integration includes models that
provide two or more services with
overlapping care teams
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care models are the provision of (1) MAT to reduce the risk for
HIV and HCV acquisition and to prevent HCV re-infection,
(2) HIV and HCV treatment to prevent transmission through
shared injection equipment and unsafe sex, (3) access to PrEP
and to syringe services programs to prevent HIV and HCV,
and (4) behavioral health services to address psychiatric co-
morbidities. Communities in different locales may require dif-
ferent models. Examples of current models of care in five
critical settings—primary care, HIV care, OPT/MAT, harm
reduction programs, and transitional clinics—provide a good
starting point for future innovation.
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